AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04187196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
Study NCT04187196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexital
Description: Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
Study NCT04383821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Trunk Mask
Description: The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
Study NCT04383821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Rebreather mask
Description: The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
Study NCT02972528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Lysate
Description: Direct injection of allogenic Platelet Lysate
Study NCT02972528 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Poor Plasma
Description: Direct injection of allogenic Platelet Poor Plasma
Study NCT01337297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
Study NCT01337297 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
Study NCT03781076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
Study NCT00803127 — intervention group
Intervention type: DEVICE
Intervention: vs-sense
Description: detection swab
Study NCT02755831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
Study NCT02755831 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-natal care
Description: Standard Pre-Natal Care
Study NCT02239536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hot snare polypectomy
Description: hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
Study NCT03818542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: intravenous infusion
Study NCT03818542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: intravenous infusion
Study NCT03818542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: intratumoral injection
Study NCT00988039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aluvia + 2NRTIs
Description: Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.
Study NCT02239536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hot snare polypectomy after saline injection
Description: hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
Study NCT00096044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV
Study NCT00096044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral
Study NCT03139916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide causes cell death and shrinks and kills the cancer cells
Study NCT03139916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab may activate (cause) the immune system to attack the cancer cells
Study NCT03139916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation causes cell death and shrinks and kills the cancer cells.
Study NCT01620580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3
Study NCT01620580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Information
Description: The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
Study NCT01957475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Y
Description: Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
Study NCT01957475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Z
Description: Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
Study NCT02467725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic culture platform
Description: Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
Study NCT03407872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
Study NCT03407872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high.
Study NCT03407872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high.
Study NCT03407872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.
Study NCT02977234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoamyl 2-Cyanoacrylate
Study NCT03567863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®
Description: The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
Study NCT03567863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®
Description: The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
Study NCT01420081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 154mg IV weekly
Study NCT04696705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded allogeneic γδT cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
Study NCT03784950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rating tool
Description: eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
Study NCT03784950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
Study NCT04534842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
Study NCT04534842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
Study NCT01613339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training using Body awareness therapy
Description: Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
Study NCT03822728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-DESS MRI (3 dimensional double echo steady state MRI)
Description: 3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT05137964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Serum Biochemical routine lab workup and gynaecological ultra sound AFC
Study NCT00988039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluvia + raltegravir
Description: Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily
Study NCT04628780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209960
Description: PD-1 targeted IL-15 mutein
Study NCT00988039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluvia monotherapy
Description: Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only
Study NCT02401165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: blood test
Study NCT03254199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT (orally disintegrating tablet)
Description: FLX-787-ODT taken three times daily for 28 days
Study NCT03254199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ODT
Description: Placebo ODT taken three times daily for 28 days
Study NCT00778115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide HCl 2 mg and simethicone 125 mg tablets
Study NCT00778115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide HCl 2 mg and simethicone 125 mg tablets
Study NCT03884790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical repair of long bone defects
Description: Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects.
Study NCT01492205 — intervention group
Intervention type: DRUG
Intervention: insulin human
Description: All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021 placebo
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021 placebo
Study NCT02792400 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal
Study NCT02792400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: DPP-4-inhibitor
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin placebo
Study NCT00421681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Exercise Program
Description: Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
Study NCT02392806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP- BabiPlus, Respiralogics
Description: Infant will be randomized to BabiPlus Bubbler at time of extubation
Study NCT02392806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP- B&B Bubbler, B&B Medical devices
Description: Infant will be randomized to B\&B Bubbler at time of extubation
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: SGLT2-inhibitor
Study NCT02792400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin placebo
Study NCT02768935 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blodd sample at 12 months
Study NCT00503269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Hemorrhoidectomy under local anaesthesia
Study NCT00503269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: General anaesthetic haemorrhoidectomy
Study NCT05598281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet
Study NCT05598281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablet
Study NCT04378270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PopSole™ Offloading Device
Description: Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
Study NCT03035799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Description: Paleolithic diet
Study NCT03035799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Healthful Diet
Description: General Healthful Diet
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02915744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT01461434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Reveal XT implantable loop recorder
Description: subcutaneous implantation
Study NCT00965393 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
Study NCT00965393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
Study NCT00965393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Systemic infusion of placebo (saline)
Study NCT00965393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bradykinin receptor antagonist (HOE-140)
Description: Systemic infusion of bradykinin receptor antagonist (HOE-140)
Study NCT00618800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
Study NCT00618800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Materials
Description: Participants receive written information about falls prevention.
Study NCT00557986 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary surgery
Description: Primary breast surgery before systemic therapy
Study NCT04187937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic image-guided resection
Description: Stereotactic image-guided resection with an ultrasound-based image-guidance system.
Study NCT05592704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises
Description: Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
Study NCT00902486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 4 mg capsules QD
Study NCT00902486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 7 mg capsules QD
Study NCT00902486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 10 mg capsule QD
Study NCT00902486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching INCB028050 QD
Study NCT02058459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holaira™ Lung Denervation System with energy delivery